A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Inclusion Criteria:

1. Male or female subjects aged ≥ 18 years.
2. Subjects diagnosed with moderate-to-severe plaque psoriasis for at least 6 monthsbefore screening.
3. At screening and baseline, PASI score ≥ 12, Body Surface Area BSA (BSA) ≥ 10%, sPGA ≥
5. Subjects with a history of an inadequate response, intolerable or medicallyinappropriate use of systemic therapy and/or phototherapy.
6. Subjects who are women of childbearing potential must have a negative pregnancy testat screening and must be practicing an adequate, medically acceptable method of birthcontrol for at least 6 months after the last study drug administration.

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type psoriasis.
2. History or evidence of active TB. Patients with evidence of latent tuberculosis mayenter the trial after sufficient treatment had initiated and maintained according toprotocol.
3. Positive results of confirmatory test for hepatitis B, hepatitis C, humanimmunodeficiency virus (HIV) or syphilis.
4. History of repeated chronic infection, had any serious infection or systemic infectionwithin 2 months before screening.
5. History of prohibited psoriasis treatments within 2/4 weeks before randomization.
6. History of IL12/23 or IL-23 inhibitors therapy.
7. Inadequate washout period of prior biological therapy.
8. History of malignant tumour within 5 years before screening.
9. Any medical or psychiatric condition, laboratory, or ECG parameter which, in theopinion of the Investigator would place the subject at risk, interfere withparticipation or interpretation of the study.